Physician profile
Steven L Seese
NPI 1053846725
$1,669.05
in general payments reported to CMS, 2019-2025
17 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.92 · 2022: $75.31 · 2023: $446 · 2024: $678 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $321.64 | 2022-2025 | Vraylar |
| Corium, LLC | $210.54 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $205.97 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Axsome Therapeutics, INC. | $190.46 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $147.24 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $116.05 | 2019-2025 | Fanapt |
| Lundbeck LLC | $107.77 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $100.76 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $85.23 | 2023-2024 | Spravato, Invega |
| Teva Pharmaceuticals USA, INC. | $44.70 | 2023-2024 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $29.51 | 2023 | Trintellix |
| Shire North American Group INC | $27.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.62 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $16.58 | 2019 | |
| Neos Therapeutics, Lp | $15.70 | 2023 | Adzenys Xr-Odt |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.46 | 2025 | Caplyta |
| Tris Pharma INC | $13.75 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Seese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.